STOCK TITAN

Oramed grants CFO Gabay 357,000-share conditional award

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

ORAMED PHARMACEUTICALS INC. granted Chief Financial Officer Avraham Gabay two restricted stock awards on November 12, 2026: 357,000 shares and 242,000 shares, under its Amended and Restated 2019 Stock Incentive Plan. The 357,000-share award vests only if fiscal 2026 return on equity exceeds 18% and is subject to continued service. The 242,000-share award represents annual awards for fiscal years 2027 and 2028 and vests in quarterly installments, subject to continued service. The company stated that no annual award will be granted for fiscal 2028.

Insider Gabay Avraham
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Common Stock F1 357,000 -- --
Grant/Award Common Stock F2 242,000 -- --
Holdings After Transaction: Common Stock — 1,460,076 shares (Direct)
Holdings Before and After: Common Stock, 861,076 to 1,460,076 shares (Direct)
Footnotes (2)
  1. F1. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 357,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan. The shares vest only if the issuer's return on equity for fiscal year 2026 exceeds 18%, in which case 50% vest on the date the issuer's audited fiscal year 2026 financial statements are published and 50% vest six months thereafter, subject to the reporting person's continued service. If the condition is not met, all of the shares will be forfeited.
  2. F2. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 242,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's annual awards for fiscal years 2027 and 2028. Of these shares, 121,000 vest in twelve substantially equal quarterly installments beginning January 1, 2027, and 121,000 vest in twelve substantially equal quarterly installments beginning January 1, 2028, in each case subject to the reporting person's continued service. No annual award will be granted to the reporting person for fiscal year 2028.
Restricted stock award 357,000 shares Granted November 12, 2026; fiscal 2026 return on equity must exceed 18% for vesting
Return on equity vesting condition Exceeds 18% Fiscal year 2026 condition for the 357,000-share award
Award vesting portions 50% each For the 357,000-share award; first portion vests upon publication of audited fiscal 2026 financial statements and the second six months later
Restricted stock award 242,000 shares Granted November 12, 2026; represents annual awards for fiscal years 2027 and 2028
First award portion 121,000 shares Vests in 12 substantially equal quarterly installments beginning January 1, 2027, subject to continued service
Second award portion 121,000 shares Vests in 12 substantially equal quarterly installments beginning January 1, 2028, subject to continued service
restricted stock award financial
"granted to the reporting person a restricted stock award"
A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.
return on equity financial
"issuer's return on equity for fiscal year 2026 exceeds 18%"
Return on equity shows how effectively a company uses its shareholders' money to generate profit. It is calculated by dividing the company's net profit by its shareholders' equity, indicating how much profit is earned for each dollar invested by owners. Higher return on equity suggests the company is good at turning investments into earnings, which can be an important factor for investors assessing its profitability and efficiency.
vest financial
"shares vest only if the issuer's return on equity"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
substantially equal quarterly installments financial
"vest in twelve substantially equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did ORMP grant its CFO?

ORAMED PHARMACEUTICALS INC. granted Chief Financial Officer Avraham Gabay restricted stock awards covering 357,000 shares and 242,000 shares on November 12, 2026, under its Amended and Restated 2019 Stock Incentive Plan.

What are the vesting conditions for Avraham Gabay’s 357,000-share ORMP award?

The award vests only if ORAMED PHARMACEUTICALS INC.’s return on equity for fiscal year 2026 exceeds 18%. If that condition is met, 50% vests when the issuer’s audited fiscal 2026 financial statements are published and 50% six months later, subject to Gabay’s continued service. Otherwise, all shares are forfeited.

How does Avraham Gabay’s 242,000-share ORMP award vest?

The award is divided into two 121,000-share portions, each vesting in 12 substantially equal quarterly installments, subject to continued service. Installments for the first portion begin January 1, 2027, and those for the second begin January 1, 2028. The award represents annual awards for fiscal years 2027 and 2028; no annual award will be granted for fiscal 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gabay Avraham

(Last)(First)(Middle)
1185 AVENUE OF THE AMERICAS
THIRD FLOOR

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/12/2026A357,000A(1)1,218,076D
Common Stock11/12/2026A242,000A(2)1,460,076D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 357,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan. The shares vest only if the issuer's return on equity for fiscal year 2026 exceeds 18%, in which case 50% vest on the date the issuer's audited fiscal year 2026 financial statements are published and 50% vest six months thereafter, subject to the reporting person's continued service. If the condition is not met, all of the shares will be forfeited.
2. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 242,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's annual awards for fiscal years 2027 and 2028. Of these shares, 121,000 vest in twelve substantially equal quarterly installments beginning January 1, 2027, and 121,000 vest in twelve substantially equal quarterly installments beginning January 1, 2028, in each case subject to the reporting person's continued service. No annual award will be granted to the reporting person for fiscal year 2028.
/s/ Avraham Gabay11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading